Understanding Endo International’s Operational Performance
How's Endo International Positioned in December? For fiscal 2018 and 2019, Endo is expected to incur research and development expenses of $162.01 million and $165.43 million, respectively. Endo expects its US generic pharmaceuticals research and development costs to decline due to its moving its R&D activities to India.